RISANKIZUMAB (Skyrizi®)
Clinical Indication
For previously treated moderately to severely active Crohn's disease
Comments
In line with NICE TA888
Date of classification
October 2023
Red
Medicines which should be prescribed only in a specialist setting usually within a secondary or tertiary care service. NB: Some highly specialised RED medicines e.g. injectable treatments for cancer are not included on the LLR APC website list.